about the author

Kyle Blankenship

kyle@endpointsnews.com @ka_blankenship
Kyle Blankenship on LinkedIn

author articles

#ACC21: No­var­tis' En­tresto takes its 2nd fail­ure of the week­end at ACC, show­ing no ben­e­fit in most dire heart fail­ure ...

4 years ago
R&D
Pharma

A T-cell play­er with back­ing from Roche takes next big step for BiTE drugs with 'on-of­f' switch to avoid tox­i­c­i­ty

4 years ago
Financing
Startups

#ACC21: As­traZeneca's Farx­i­ga missed big on Covid-19 study, but it's tak­ing SGLT2 safe­ty da­ta as a sil­ver lin­ing

4 years ago
R&D
Pharma

#ACC21: Re­gen­eron's Evkeeza shows promise in curb­ing high triglyc­erides, but will ge­net­ic dis­par­i­ties lim­it use?

4 years ago
R&D
Pharma

#ACC21: Pfiz­er, Bris­tol My­er­s' Eliquis flops in post-heart surgery pa­tients, spurring an 'un­ex­plained sig­nal' in ...

4 years ago
R&D
Pharma

#ACC21: Bris­tol My­ers backs up its case for heart drug mava­camten as FDA weighs app in car­diomy­opa­thy

4 years ago
R&D

#ACC21: No­var­tis whiffs on En­tresto study af­ter heart at­tacks — but that does­n't mean it's go­ing down qui­et­ly

4 years ago
Pharma

Apel­lis bags FDA nod for Soliris chal­lenger with a dif­fer­ent path­way to PNH — but can it slay the gi­ant?

5 years ago
FDA+

PerkinElmer hits the check­book again, this time dol­ing out $260M for next-gen ther­a­py bioser­vices firm

5 years ago
Deals
Manufacturing

A Third Rock-backed play­er charts a new course against tran­scrip­tion fac­tors. Do 'switch sites' hold the mag­ic sauce?

5 years ago
Financing
Startups

A non-opi­oid pain start­up be­lieves it can top the bupi­va­caine mar­ket — and it's think­ing in terms of weeks, not ...

5 years ago
Startups

Sanofi, Cel­lec­tis team up to pair Lem­tra­da with al­lo­gene­ic CAR-Ts; Bris­tol My­ers joins Evotec's dri­ve to ad­vance UK ...

5 years ago
News Briefing

An Ab­b­Vie clin­i­cal vet head­ing ear­ly on­col­o­gy jumps ship to build his own team at NK cell-fo­cused biotech

5 years ago
People
Cell/Gene Tx

No­bel lau­re­ate David Bal­ti­more throws his weight be­hind I/O start­up look­ing to craft off-the-shelf CAR ther­a­pies

5 years ago
Financing
Cell/Gene Tx

Ab­b­Vie makes a hefty play to boost aes­thet­ics busi­ness, pay­ing $550M for non-in­va­sive body sculpt­ing de­vice

5 years ago
Deals
Pharma

The com­pa­ny be­hind Mod­er­na has a new RNA start­up look­ing to dis­rupt drug­mak­ing. The goal? 100 new drugs in 10 years

5 years ago
Financing
Startups

As­traZeneca, Dai­ichi Sankyo un­cork new TNBC da­ta for 2nd part­nered ADC — and it's adding more heat un­der Gilead­'s ...

5 years ago
R&D

In­cyte ponies up $12M to set­tle char­i­ty foun­da­tion kick­back claims; US ex­er­cis­es op­tion for more dos­es of mon­key­pox ...

5 years ago
News Briefing

Gold­man Sachs jumps aboard Bain-backed 503(b) com­pound­ing phar­ma­cy with a $275M debt loan to sup­ply hos­pi­tals

5 years ago
Financing
Outsourcing

Catal­ent snaps up Promether­a's cell ther­a­py sub­sidiary, com­plete with a Bel­gian plant to help scale plas­mid DNA ...

5 years ago
Outsourcing
Manufacturing

Dyno's Er­ic Kel­sic fills the tank in his quest for bet­ter AAV with a group of big-name sup­port­ers on board

5 years ago
Financing
AI

An em­ploy­ee com­plaint at Eli Lil­ly's Branch­burg plant al­leges al­tered qual­i­ty con­trol docs amid FDA probe — re­port

5 years ago
Pharma
Coronavirus

Ada­gio of­fers first peek at Covid-19 an­ti­body da­ta, with pre­ven­ta­tive num­bers that may ri­val mR­NA vac­cines

5 years ago
R&D
Coronavirus

Vik Ba­ja­j's start­up in­cu­ba­tor at Fore­site un­cloaks an im­munol­o­gy play­er with a lead TYK2 in­hibitor in tow

5 years ago
Financing
Startups
First page Previous page 10111213141516 Next page Last page
A service from the Financial Times